American depositary receipt

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Evolution AB (publ) Investors to Secure Counsel Before Important Deadline in Securities Class Action - EVVTY

Retrieved on: 
onsdag, mars 6, 2024

WHAT TO DO NEXT: To join the Evolution class action, go to https://rosenlegal.com/submit-form/?case_id=22119 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Evolution class action, go to https://rosenlegal.com/submit-form/?case_id=22119 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Renesas Extends Tender Offer for Proposed Acquisition of Sequans

Retrieved on: 
tisdag, februari 20, 2024

Shareholders to Receive U.S. $0.7575 per Ordinary Share and U.S. $3.03 per ADS in cash

Key Points: 
  • Renesas is of the opinion that this confirmation constitutes an Adverse Japanese Tax Ruling under the Memorandum of Understanding and, therefore, the contractual condition in the Memorandum of Understanding to the tender offer requiring Renesas' receipt of a confirmation that such reorganization not trigger such tax cannot be fulfilled.
  • On February 12, 2024, the parties closed another financing transaction in which a wholly owned subsidiary of Renesas loaned an additional $9,000,000 to Sequans in exchange for an unsecured subordinated note of Sequans.
  • The tender offer was extended to allow additional time for the satisfaction of the remaining closing conditions of the tender offer, including, but not limited to, the valid tender of ordinary shares and ADSs of Sequans representing - together with ordinary shares and ADSs of Sequans beneficially owned by Renesas, if any - at least 90% of the fully diluted ordinary shares of Sequans.
  • The Bank of New York Mellon, the Tender Agent for the tender offer, has advised Renesas that as of 6 p.m., New York City time, on February 16, 2024, approximately 123,472,744 ordinary shares of Sequans (including ordinary shares represented by ADSs), representing approximately 44.5% of the fully diluted ordinary shares of Sequans, have been validly tendered and not properly withdrawn pursuant to the tender offer.

Attention Sibanye Stillwater Limited Investors: Company Investigated by the Portnoy Law Firm

Retrieved on: 
måndag, mars 11, 2024

​LOS ANGELES, March 11, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Sibanye Stillwater Limited (“Sibanye” or the “Company”) (NYSE: SBSW) investors that the law firm has initiated an investigation on behalf of investors that lost money on their Sibanye stock. Sibanye investors are encouraged to contact the firm to discuss their legal rights.

Key Points: 
  • ​LOS ANGELES, March 11, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Sibanye Stillwater Limited (“Sibanye” or the “Company”) (NYSE: SBSW) investors that the law firm has initiated an investigation on behalf of investors that lost money on their Sibanye stock.
  • Sibanye investors are encouraged to contact the firm to discuss their legal rights.
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing.

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Evolution AB (publ) Investors to Secure Counsel Before Important Deadline in Securities Class Action – EVVTY

Retrieved on: 
måndag, mars 11, 2024

WHAT TO DO NEXT: To join the Evolution class action, go to https://rosenlegal.com/submit-form/?case_id=22119 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Evolution class action, go to https://rosenlegal.com/submit-form/?case_id=22119 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market

Retrieved on: 
måndag, mars 11, 2024

Lyon (France) and Cambridge (MA, US), March 11, 2024, at 07:00am CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today announces that the Company’s voluntary delisting of American Depositary Shares (“ADSs”) representing its ordinary shares from The Nasdaq Capital Market (“Nasdaq”) has become effective.

Key Points: 
  • Lyon (France) and Cambridge (MA, US), March 11, 2024, at 07:00am CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today announces that the Company’s voluntary delisting of American Depositary Shares (“ADSs”) representing its ordinary shares from The Nasdaq Capital Market (“Nasdaq”) has become effective.
  • The Bank of New York Mellon serves as depositary (the “Depositary”) for the Company’s ADS facility.
  • On or about May 28, 2024, the Depositary may elect to sell the underlying ordinary shares.
  • Investors will receive either the underlying ordinary shares (if those have not yet been sold by the Depositary) or the cash received by the Depositary received upon sale of underlying ordinary shares, net of fees, if those underlying ordinary shares were sold.

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Evolution AB (publ) Investors to Secure Counsel Before Important Deadline in Securities Class Action – EVVTY

Retrieved on: 
lördag, mars 9, 2024

WHAT TO DO NEXT: To join the Evolution class action, go to https://rosenlegal.com/submit-form/?case_id=22119 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Evolution class action, go to https://rosenlegal.com/submit-form/?case_id=22119 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Trinity Biotech Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

Retrieved on: 
fredag, mars 8, 2024

DUBLIN, Ireland, March 08, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech Plc.

Key Points: 
  • DUBLIN, Ireland, March 08, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech Plc.
  • (NASDAQ: TRIB) (the “Company”) today reported the receipt of a formal notification from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Listing Rule 5450(a)(1), which requires the Company's American Depositary Shares (“ADSs”) to maintain a minimum bid price of $1.00 per ADS.
  • The Nasdaq staff made this determination of compliance after the closing bid price of the Company's was at $1.00 per share or greater for the prior 10 consecutive business days.
  • Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5450(a)(1) and Nasdaq considers the prior bid price deficiency matter now closed.

QuantaSing Announces Unaudited Financial Results for the Second Quarter of Fiscal Year 2024

Retrieved on: 
torsdag, mars 7, 2024

BEIJING, March 07, 2024 (GLOBE NEWSWIRE) -- QuantaSing Group Limited (NASDAQ: QSG) (“QuantaSing” or the “Company”), a leading online learning service provider in China, today announced its unaudited financial results for the second quarter of the fiscal year ending June 30, 2024 (the “second quarter of FY 2024”, which refers to the quarter from October 1, 2023 to December 31, 2023).

Key Points: 
  • BEIJING, March 07, 2024 (GLOBE NEWSWIRE) -- QuantaSing Group Limited (NASDAQ: QSG) (“QuantaSing” or the “Company”), a leading online learning service provider in China, today announced its unaudited financial results for the second quarter of the fiscal year ending June 30, 2024 (the “second quarter of FY 2024”, which refers to the quarter from October 1, 2023 to December 31, 2023).
  • Revenues for the second quarter of FY 2024 were RMB980.5 million (US$138.1 million), representing an increase of 12.8% from the first quarter of the fiscal year ending June 30, 2024 (the “first quarter of FY 2024”) and an increase of 24.7% from the second quarter of the fiscal year ended June 30, 2023 (the “second quarter of FY 2023”).
  • Net income for the second quarter of FY 2024 was RMB107.6 million (US$15.2 million), compared with RMB66.7 million in the first quarter of FY 2024, and a net loss of RMB41.4 million in the second quarter of FY 2023.
  • Adjusted net income2 for the second quarter of FY 2024 was RMB103.9 million (US$14.6 million), compared with RMB94.0 million in the first quarter of FY 2024, and RMB21.8 million in the second quarter of FY 2023.

DBV Technologies Reports Full Year 2023 Financial Results and Business Update

Retrieved on: 
torsdag, mars 7, 2024

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today reported financial results for the full year 2023.

Key Points: 
  • DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today reported financial results for the full year 2023.
  • Published EPITOPE results in the New England Journal of Medicine with an accompanying editorial, entitled, Good News for Toddlers with Peanut Allergy.
  • ET to discuss full year 2023 financial results and provide a business update.
  • The conference call may be accessed by dialing:
    A webcast of the call will also be available under "Events" in the Investors section of the DBV Technologies website: https://dbv-technologies.com/investor-overview/events .

EVVTY INVESTORS: Lead Plaintiff Deadline is Fast Approaching; Contact Robbins LLP for Information About the Evolution AB (publ) Class Action

Retrieved on: 
onsdag, mars 6, 2024

For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.

Key Points: 
  • For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against Evolution AB.
  • Shareholders who want to act as lead plaintiff for the class should contact Robbins LLP.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.